Southwest Oncology Group

描述（由申请人提供）：韦恩州立大学（WSU）30多年来一直是西南肿瘤组的活跃机构成员，招募了4000多名患者参加临床试验。在这些年来，我们的教师在支持SWOG发挥了重要作用，通过在SWOG的行政和科学职能提供领导，并通过会议和超越患者的累积目标，在持续和一致的方式。因此，在过去五年中，WSU一直处于SWOG进行的机构绩效评估的第一个四分位数。华盛顿州立大学的癌症临床研究计划是沿着多学科疾病导向研究的路线组织的，其方式类似于SWOG的器官委员会方向。因此，我们的教师在科学SWOG委员会的代表是由具有专业知识和致力于这些研究领域的个人组成。因此，很容易将想法转化为SWOG研究，并将SWOG研究和NCI指定的高优先级试验纳入WSU治疗优先级。此外，我们地区的人口统计数据以及研究者向所有患者提供临床试验的承诺，在我们招募少数民族（27%）和女性（61%）参加SWQG临床试验时得到了明确的确认。在WSU的SWOG成员和我们的教师学科参与的多样性多年来一直在不断增长。到目前为止，100多名WSU成员目前在40多个委员会任职。同样，自上次提交竞争申请以来，50项SWOG研究将WSU成员列为研究主要协调员或协调员。第五，三个摘要和56个手稿有WSU教师作为主要或共同作者。六名WSU医师和三名护士担任14个委员会的行政职务。自上一次竞争性续约以来，WSU已获得NCl补充赠款，用于化学预防和少数族裔招募。Lawrence Flaherty博士自1986年以来一直是SWOG成员，并担任SWOG黑色素瘤委员会副主席，自1996年以来一直担任首席研究员，并保持了WSU作为SWOG成员机构的突出地位。

DESCRIPTION (provided by applicant): Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 30 years, enrolling over 4000 patients onto clinical trials. Over these years, our faculty have played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution's performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented studies and in a manner that resembles the organ committee orientation of SWOG. Thus, our faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment toward those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities, are easily facilitated. In addition, the demographics of our region and the commitment of investigators to make clinical trials available to all patients, is clearly identified in our recruitment of minorities (27%) and women (61%) into SWQG clinical trials. The SWOG membership in WSU and the diversity of disciplinary involvement by our faculty has continued to grow over the years. To date over 100 WSU members are currently serving on over 40 committees. Similarly, 50 SWOG studies list a WSU member as a study primary coordinator or co-coordinator since the last competing application was submitted. Fifth three abstracts and 56 manuscripts have had WSU faculty as primary or co-authors. Six WSU physician faculty and 3 nurses hold 14 committee administrative roles. Since the last competitive renewal WSU has been awarded NCl supplemental grants for chemoprevention and minority recruitment. Dr. Lawrence Flaherty, a SWOG member since 1986 and Vice-Chairman of the SWOG Melanoma Committee, has been the Principal Investigator since 1996 and has maintained the prominence of WSU as a SWOG member institution.